IOVA - Latest News

Iovance Biotherapeutics, Inc. (IOVA), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $3.12B. Beta to the broader market is 0.70.

The article list below shows the most recent IOVA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent IOVA Headlines

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

fool.com - Aug 10, 2026

Iovance's revenue rose 66% last quarter due to strong demand for Amtagvi. The company also cut its losses by nearly 60%.

IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake

zacks.com - Aug 7, 2026

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?

zacks.com - Aug 7, 2026

The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has

Iovance Biotherapeutics Q2 Earnings Call Highlights

marketbeat.com - Aug 6, 2026

Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymp

Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due September

seekingalpha.com - Aug 6, 2026

Iovance Biotherapeutics is rated a buy, driven by strong Q2 results, surging Amtagvi sales, and promising pipeline catalysts. Q2 product revenues rea

How News Affects IOVA Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IOVA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked IOVA news questions

What is the latest IOVA news headline?

The most recent IOVA headline (Aug 10, 2026) is "Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the IOVA news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What IOVA news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual IOVA options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.